AEYE-DS Diagnostic Screening

Description

AEYE-DS is a cutting-edge AI-based diagnostic screening solution developed by AEYE Health, a digital health company founded in 2019 in New York City. This innovative tool is designed to provide fully autonomous screening for diabetic retinopathy, a common complication of diabetes that can lead to blindness if not detected early. AEYE-DS is the first and only FDA-cleared solution that offers instant AI diagnosis using both portable and tabletop cameras, making it highly versatile and accessible.

The system is designed to be used at the point of care, allowing primary care physicians to screen patients on the spot without the need for specialist referrals. This not only speeds up the diagnostic process but also helps close the diabetic retinopathy care gap, particularly in underserved communities where access to specialist care may be limited.

AEYE-DS boasts impressive performance metrics, with a sensitivity of 92%-93% and specificity of 89%-94%. It also has a success rate of over 99%, ensuring reliable and accurate results. The solution is CPT 92229 reimbursable, which can help healthcare providers manage costs effectively while improving patient outcomes.

The tool is designed for ease of use, with a 1-minute AI eye exam that requires only one image per eye. This rapid screening process provides an on-the-spot diagnostic report, eliminating the need for physician interpretation and allowing for immediate treatment decisions. AEYE-DS is particularly valuable for primary care settings, where early detection of diabetic retinopathy can prevent blindness and improve patient quality of life.

AEYE-DS Diagnostic Screening's Core Features

• Fully autonomous AI-based screening

• FDA-cleared for diabetic retinopathy

• Portable and tabletop camera compatibility

• Instant on-the-spot diagnosis

• No physician interpretation needed

• CPT 92229 reimbursable

• 92%-93% sensitivity

• 89%-94% specificity

• >99% success rate

• 1-minute exam with 1 image per eye

• Closes HEDIS gaps

• Accessible and affordable screening

How to use AEYE-DS Diagnostic Screening?

1. 1

   Configure: Set up the portable or tabletop camera

2. 2

   Use: Conduct a 1-minute AI eye exam

3. 3

   Diagnose: Receive instant on-the-spot diagnostic report

4. 4

   Treat: Make immediate treatment decisions based on results

AEYE-DS Diagnostic Screening's Use Cases

• Primary Care Screening
• Portable Camera Use
• Tabletop Camera Use
• Early Detection
• Cost Management

FAQ from AEYE-DS Diagnostic Screening

• What is AEYE-DS?

  AEYE-DS is an AI-based diagnostic screening tool for diabetic retinopathy, offering fully autonomous, FDA-cleared solutions using portable and tabletop cameras.

• How does AEYE-DS work?

  AEYE-DS uses AI to analyze retinal images, providing instant diagnosis without the need for physician interpretation.

• Is AEYE-DS FDA-cleared?

  Yes, AEYE-DS is the first and only FDA-cleared solution for AI-powered diabetic retinopathy screening with portable cameras.

• What are the performance metrics of AEYE-DS?

  AEYE-DS has a sensitivity of 92%-93%, specificity of 89%-94%, and a success rate of over 99%.

• Can AEYE-DS be used in primary care settings?

  Yes, AEYE-DS is designed for use in primary care settings, allowing on-the-spot screening and diagnosis.

• What is the exam duration with AEYE-DS?

  The AI eye exam takes just 1 minute, requiring only one image per eye.

• Is AEYE-DS reimbursable?

  Yes, AEYE-DS is CPT 92229 reimbursable, helping manage costs effectively.

• What is the benefit of using AEYE-DS?

  AEYE-DS provides practical, accurate, and accessible screening, helping prevent blindness by enabling early detection of diabetic retinopathy.